Related Experiment Video
Updated: Jan 27, 2026
A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis
Published on: August 11, 2010
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational
Michel Wassef1,2, Armelle Luscan1,2, Setareh Aflaki1,2
1Institut Curie, Paris Sciences et Lettres Research University, 75005 Paris, France.
Abstract:
Genetic mutations affecting chromatin modifiers are widespread in cancers. In malignant peripheral nerve sheath tumors (MPNSTs), Polycomb repressive complex 2 (PRC2), which plays a crucial role in gene silencing, is inactivated through recurrent mutations in core subunits embryonic ectoderm development (EED) and suppressor of zeste 12 homolog (SUZ12), but mutations in PRC2's main catalytic subunit enhancer of zeste homolog 2 (EZH2) have never been found. This is in contrast to myeloid and lymphoid malignancies, which harbor frequent loss-of-function mutations in EZH2. Here, we investigated whether the absence of EZH2 mutations in MPNST is due to a PRC2-independent (i.e., noncanonical) function of the enzyme or to redundancy with EZH1. We show that, in the absence of SUZ12, EZH2 remains bound to EED but loses its interaction with all other core and accessory PRC2 subunits. Through genetic and pharmacological analyses, we unambiguously establish that EZH2 is functionally inert in this context, thereby excluding a PRC2-independent function. Instead, we show that EZH1 and EZH2 are functionally redundant in the slowly proliferating MPNST precursors. We provide evidence that the compensatory function of EZH1 is alleviated upon higher proliferation. This work reveals how context-dependent redundancies can shape tumor-type specific mutation patterns in chromatin regulators.
Insights
Malignant peripheral nerve sheath tumors (MPNSTs) lack enhancer of zeste homolog 2 (EZH2) mutations due to functional redundancy with EZH1, not PRC2-independent activity. EZH1 compensates for EZH2 loss in MPNST precursors but this redundancy lessens with increased proliferation.
Area of Science:
- Cancer Biology
- Epigenetics
- Chromatin Regulation
Background:
- Genetic mutations in chromatin modifiers are common in cancers.
- Malignant peripheral nerve sheath tumors (MPNSTs) frequently have mutations in Polycomb repressive complex 2 (PRC2) subunits EED and SUZ12, but not EZH2.
- This contrasts with other cancers where EZH2 mutations are prevalent.
Purpose of the Study:
- To investigate why enhancer of zeste homolog 2 (EZH2) mutations are absent in MPNSTs.
- To determine if EZH2 has a PRC2-independent function or if EZH1 compensates for its loss.
- To understand the role of EZH1/EZH2 redundancy in MPNST development.
Main Methods:
- Genetic and pharmacological analyses were used to assess EZH2 function in MPNSTs.
- Investigated the interaction of EZH2 with PRC2 subunits in the absence of SUZ12.
- Examined the functional redundancy between EZH1 and EZH2 in MPNST precursors.
Main Results:
- In SUZ12-deficient MPNSTs, EZH2 remains bound to EED but loses interaction with other PRC2 components, rendering it functionally inert.
- EZH1 and EZH2 exhibit functional redundancy in slowly proliferating MPNST precursors.
- This compensatory function of EZH1 diminishes as proliferation rates increase.
Conclusions:
- The absence of EZH2 mutations in MPNSTs is due to functional redundancy with EZH1, not a PRC2-independent role of EZH2.
- Context-dependent redundancies in chromatin regulators influence tumor-specific mutation patterns.
- Understanding these redundancies is crucial for MPNST pathogenesis and therapeutic strategies.
More Related Videos
Related Concept Videos
01:39Mutations
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
02:21Cancers Originate from Somatic Mutations in a Single Cell
00:36Viral Mutations
02:52VSEPR Theory and the Basic Shapes
01:41Non-Canonical Wnt Signaling Pathways